Atea Pharmaceuticals, Inc.
AVIR•NASDAQ•Healthcare•Biotechnology

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJean-Pierre Sommadossi
Founded2012
IPO DateOctober 30, 2020
Employees56
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websiteateapharma.com
Phone857 284 8891
Address
225 Franklin Street, Suite 2100 Boston, Massachusetts 02110 United States

Corporate Identifiers

CIK0001593899
CUSIP04683R106
ISINUS04683R1068
EIN46-0574869
SIC2834

Leadership Team & Key Executives

Dr. Jean-Pierre Sommadossi Ph.D.
Founder, Chairman, Chief Executive Officer and President
Andrea J. Corcoran J.D.
Chief Financial Officer, Executive Vice President of Legal and Secretary
John F. Vavricka
Chief Commercial Officer
Dr. Janet M. J. Hammond M.D., Ph.D.
Chief Development Officer
Dr. Maria Arantxa Horga M.D.
Chief Medical Officer
Wayne Foster CPA
Executive Vice President of Finance and Chief Accounting Officer
Jonae R. Barnes
Senior Vice President of Investor Relations and Corporate Communications
Adel Moussa Ph.D.
Executive Vice President of Chemistry
Xiao-Jian Zhou Ph.D.
Executive Vice President of Early Stage Development
Keith Pietropaolo
Executive Vice President of Clinical Sciences and Project Management